Pneumonia: Update on diagnosis and management

British Medical Journal

Volumn 332, Issue 7549, 2006, Pages 1077-1079

  Hoare, Zara ^a   Lim, Wei Shen ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; HUMAN; INCIDENCE; MICROORGANISM DETECTION; PATIENT MONITORING; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; TREATMENT PLANNING; HOSPITAL DISCHARGE; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; REVIEW;

ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFUSIONS, INTRAVENOUS; PATIENT DISCHARGE; PNEUMONIA; SEVERITY OF ILLNESS INDEX;

EID: 33646474447     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.332.7549.1077     Document Type: Short Survey

References (14)

1. British Thoracic Society. Guidelines for the management of community acquired pneumonia in adults. Thorax 2001;56(suppl 4):1-64.
2. Macfarlane JT, Boldy D. 2004 update of BTS guidelines: what's new? Thorax 2004;59:364-6.
3. Metlay JP, Schulz R, Li YH, Singer DE, Marrie TJ, Coley CM, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia in the community. Arch Intern Med 1997;157:1453-9.
4. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987;I:671-4.
5. Woodhead MA, Arrowsmith J, Chamberlain-Webber R, Wooding S, Williams I. The value of routine microbial investigation in community-acquired pneumonia. Respir Med 1991;85:313-7.
6. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003;138:109-18.
7. Fine MJ, Auble TE, Yearly DM, Hanuse BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
8. Lim WS, Van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82.
9. Ewig S, Torres A, Woodhead M. Assessment of pneumonia severity: a European perspective. Eur Respir J 2006;27:6-8.
10. Weber SG, Gold HS, Hoopers DC, Karchmer AW, Carmeoli Y. Fluoroquinolones and the risk of methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003;9:1415-22.
11. Loo VE, Poirer L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
12. Hansson LO, Hedlund JU, Ortqvist A. Sequential changes of inflammatory and nutritional markers in patients with community acquired pneumonia. Scan J Clin Lab Invest 1997;57:11-8.
13. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH, et al. C-reactive protein. A clinical marker in community acquired pneumonia. Chest 1995;108:1288-91.
14. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AC. Instability on hospital discharge and the risk of adverse outcome in patients with pneumonia. Arch Intern Med 2002;162:1278-84.